News

Osiris Therapeutics is developing Prochymal in partnership with the Juvenile Diabetes Research Foundation (JDRF) as a treatment for patients with newly diagnosed type 1 diabetes mellitus. Prochymal, a

Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility; Sentry will label, package and ship the clinical supplies from its site in Indianapolis, Indiana. The collaboration will

Under the agreement, Actavis will develop, obtain US FDA approval and supply the products, which Sagent will market in the US. Jeffrey Yordon, CEO, founder and chairman of

PPD is expecting to offer medical information call center support, adverse event capture, safety case processing and reporting, and periodic report writing services from Bulgaria. Sofia is expected

The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150mg (3ml) of

The study was a randomised, double-blind, placebo controlled trial conducted at 13 centers in the US in patients with genotype 1 chronic hepatitis C, 35% of whom had

PerkinElmer claimed that the Prenatal BoBs assay is the first IVD product from the BACs-on-Beads multiplexed bead-based technology product family. The assay is a novel solution for IVD

The NDA for Ofirmev was resubmitted on May 4, 2010. The FDA is expected to determine the type of resubmission (Class 1 or Class 2) and resulting review

The 8 non-antibiotic oral formulations licensed to Alvogen under the agreement comprise products in the high growth therapeutic segments of CNS and Osteoporosis among others. Under this agreement,